Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cortiment · 1 trial · 4 indications
Cmax (Maximum plasma concentration)
AUC0-t (area under the curve)
| Arm | Type | Description |
|---|---|---|
| Cortiment (Budesonide 9 mg prolonged release tablet) | ACTIVE_COMPARATOR | - |
| Budesonide 9 mg prolonged release tablet | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Cortiment | DRUG | Budesonide 9 mg prolonged release tablets |
| Budesonide | DRUG | Experimental (Budesonide 9 mg prolonged release tablets) |
Inclusion Criteria: 1. Normal healthy human adult male and non- pregnant female volunteers between 18-45 years (both ages inclusive) of age. 2. Who is given written informed consent and are willing to participate in the study. 3. Body Mass Index of 18.50 to 30.00 Kg/m2 (both inclusive). 4. No evide...
Cortiment is an investigational small molecule drug being developed by Abbott Laboratories. It is a prolonged-release tablet formulation of budesonide. Abbott is listed under the ticker ABT. The drug is in Phase 1 clinical development, and the specific therapeutic indication has not been disclosed.
Cortiment is being developed by Abbott Laboratories, which trades under the ticker symbol ABT. Abbott is the sponsor of the clinical program for this drug candidate.
Cortiment is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA.
Cortiment has been studied in one completed Phase 1 trial, NCT05519514, titled Bio-Equivalence Study of Budesonide Prolonged-release Tablets 9 Mg In Healthy Human Adult Subjects. The trial enrolled 56 healthy adult participants in India and was active-controlled and randomized.
Cortiment is a prolonged-release tablet formulation containing budesonide as the active ingredient. It is not a different drug substance but a specific oral formulation of budesonide developed by Abbott Laboratories.